Skip to main content

Table 4 Cox proportional hazards regression analysis of association between potential factors and death after PPV in the 100 CRPC patients

From: A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time

Factors

Cut-offsa

Univariate

Multivariate

  

p value

Hazard ratio

95% CI

p value

Hazard ratio

95% CI

IgG response

Positive vs. negative

<0.0001

0.19

0.101-0.355

0.001

0.272

0.125-0.592

ECOG performance status

0 vs. 1

<0.0001

0.073

0.031-0.174

0.004

0.179

0.056-0.569

CRP

Low (<3000 ng/mL) vs. high

0.012

0.461

0.252-0.842

0.006

0.389

0.199-0.759

PSADT

Increase (2 times) vs. no

0.018

0.477

0.258-0.881

0.004

0.357

0.176-0.725

PSA

Low (<30 ng/mL) vs. high

0.004

0.407

0.221-0.749

0.008

0.361

0.171-0.762

Prior chemotherapy

Untreated vs. treated

0.037

0.536

0.298-0.962

0.329

0.695

0.335-1.445

T-cell response

Positive vs. negative

0.039

0.51

0.269-0.967

0.273

0.679

0.340-1.357

>50% PSA decline

Positive vs. negative

0.046

0.387

0.152-0.984

0.553

0.733

0.263-2.042

Number of lymphocytes

High (>1300/μL) vs. low

0.054

0.562

0.313-1.009

-

-

-

IL6

Low (<2.4 pg/mL) vs. high

0.057

0.491

0.236-1.021

-

-

-

Pts. age

Low (<69 years) vs. high

0.186

0.666

0.364-1.218

-

-

-

Gleason score

Low (<8) vs. high

0.623

1.162

0.637-2.128

-

-

-

SAA

Low (<8 μg/mL) vs. high

0.709

0.875

0.433-1.767

-

-

-

  1. Of the 100 men, 64 died.
  2. aLymphocyte, PSA, and patient age are based on median values.
  3. Abbreviations: PPV, personalized peptide vaccination; CRPC, castration-resistant prostate cancer; CI, confidence intervals; ECOG, Eastern Cooperative Oncology Group; PSA, prostate-specific antigen; PSADT, PSA doubling time; CRP, C-reactive protein; SAA, serum amyloid A; IL6, interleukin 6.